Company: BGLC
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001477932-25-002725
Chunk: 77

Company: BioNexus Gene Lab Corp
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1C
Chunk 77
---
 expense  -   (3,494)  -   (3,494)                 NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS  $(246,939) $(206,586) $(1,144,817) $(1,598,342)    Provision for genomic screening services  Trading of industrial chemicals  Investment holding  Total   Year ended December 31, 2023              Segment assets  $2,522,321  $6,676,344  $2,201,128  $11,399,793                  Included in the measure of segment assets are:                 Addition to non-current assets other than financial instruments and deferred tax assets  247,192   15,486   -   262,678     Provision for genomic screening services  Trading of industrial chemicals  Investment holding  Total   Year ended December 31, 2024              Segment assets  $2,652,754  $6,788,302  $992,792  $10,433,848                  Included in the measure of segment assets are:                 Addition to non-current assets other than financial instruments and deferred tax assets  150,881   221,844   -   372,725   The Company had no inter-segment sales for the years presented. 

 F-27Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE YEAR ENDED DECEMBER 31, 2024 AND 2023 

(Currency expressed in United States Dollars (“US$”)) 

(Audited)

NOTE 14 - SIGNIFICANT EVENTS On January 12, 2024, our subsidiary, MRNA Scientific issued a termination notice to one of our suppliers for failing to deliver hardware of merchantable quality, for a contract with the value of MYR500,000 (approximately USD $109,000). Through subsequent negotiations, MRNA Scientific has been offered a without prejudice settlement of MYR350,000 (approximately USD $76,000) via a letter from the suppliers’ legal counsel, dated March 21, 2024. On 30 May 2024, the supplier had